Mobius Therapeutics, LLC
Mobius Therapeutics, LLC, headquartered in the United States, is a pioneering company in the pharmaceutical industry, specialising in innovative ophthalmic solutions. Founded in 2013, Mobius has made significant strides in developing unique products that enhance patient care in the field of eye health. The company is renowned for its flagship product, Mitosol, a proprietary formulation of mitomycin-C, which is specifically designed for use in glaucoma and cataract surgeries. This product stands out due to its advanced delivery system, ensuring precise application and improved outcomes for patients. With a strong market position, Mobius Therapeutics has garnered recognition for its commitment to quality and innovation, making it a trusted name among healthcare professionals. The company continues to expand its operational reach, focusing on enhancing surgical techniques and patient safety in ophthalmology.
DitchCarbon Score
How does Mobius Therapeutics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mobius Therapeutics, LLC's score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mobius Therapeutics, LLC's reported carbon emissions
Mobius Therapeutics, LLC, headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their carbon emissions in kg CO2e, nor are there any documented initiatives aimed at reducing their carbon footprint. In the absence of specific emissions data, it is important to note that many companies in the pharmaceutical and biotechnology sectors are increasingly committing to sustainability and climate action. This often includes setting science-based targets for emissions reductions and participating in global climate initiatives. However, without concrete information from Mobius Therapeutics, it is unclear what specific commitments or strategies they may have in place regarding climate change and carbon emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mobius Therapeutics, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
